Should Everyone Take Calcium and Vitamin D?

Who Actually Needs Calcium and Vitamin D Supplements?

Most healthy adults eating a varied diet do not need calcium or vitamin D supplements. Supplementation is appropriate when dietary intake falls below the Recommended Dietary Allowance, when serum 25-hydroxyvitamin D sits below 20 ng/mL, or when fracture risk is elevated by conditions such as celiac disease, inflammatory bowel disease, glucocorticoid use, or postmenopausal bone loss.

The National Institutes of Health sets the RDA for calcium at 1 to 000 mg per day for adults aged 19 to 50, rising to 1 to 200 mg per day for women over 51 and men over 70 [1]. One cup of plain low-fat yogurt delivers roughly 415 mg of calcium. Two cups of fortified milk add another 600 mg. Many adults who consume dairy, leafy greens, and fortified foods meet the RDA without any pill. The problem is that a meaningful minority do not.

For vitamin D, the Endocrine Society's 2011 clinical practice guideline (reaffirmed in subsequent publications) defined deficiency as a 25-OH-D below 20 ng/mL and insufficiency as 20 to 29 ng/mL [2]. NHANES data from 2001 to 2014 estimated that approximately 29% of U.S. adults had levels below 20 ng/mL, with Black and Hispanic adults disproportionately affected due to melanin-related differences in cutaneous synthesis [3]. Those individuals benefit from supplementation. Individuals with replete levels, particularly above 40 ng/mL, do not benefit from additional vitamin D and may face hypercalcemia at sustained intakes above 10 to 000 IU per day.

The USPSTF issued a 2021 grade D recommendation against daily supplementation with 400 IU or less of vitamin D and 1 to 000 mg or less of calcium for primary prevention of fractures in postmenopausal women, citing lack of net benefit at those doses [4]. That recommendation covers prevention in low-risk populations, not treatment of confirmed deficiency or osteoporosis.

The Cardiovascular Signal From Calcium Supplements

Calcium from food does not carry the same cardiovascular risk signal as calcium from supplements. This is a clinically important distinction.

A 2010 meta-analysis in the BMJ (Bolland et al., N=12,000 across 11 trials) found that calcium supplementation alone was associated with a 27% to 31% increase in myocardial infarction risk [5]. The effect was not seen with dietary calcium. The proposed mechanism involves transient supraphysiologic serum calcium peaks after bolus supplementation, which may promote vascular calcification.

The Women's Health Initiative trial (N=36,282) did not replicate that magnitude of cardiovascular harm at 1 to 000 mg supplemental calcium plus 400 IU vitamin D3, though post-hoc analyses suggested a possible signal in women not taking personal calcium supplements at baseline [6]. The VITAL trial (N=25,871) found no significant cardiovascular benefit or harm from 2 to 000 IU vitamin D3 daily over 5.3 years [7].

Practical implication: if a patient's dietary calcium already reaches 800 to 1 to 000 mg per day, adding a 500 mg supplement produces little skeletal benefit and adds unnecessary cardiovascular exposure. A 24-hour dietary recall or food frequency questionnaire should precede any supplement recommendation.

Vitamin D3, Vitamin K2, and Why the Pairing Matters

Vitamin D3 (cholecalciferol) is the preferred supplemental form over vitamin D2 (ergocalciferol). A 2012 meta-analysis in the American Journal of Clinical Nutrition found D3 was approximately 87% more potent at raising and maintaining serum 25-OH-D concentrations than D2 [8].

Vitamin K2 (menaquinone-7) is increasingly paired with D3 in clinical practice because carboxylation of osteocalcin and matrix Gla protein depends on adequate K2 status. Osteocalcin directs calcium into bone matrix. Matrix Gla protein inhibits arterial calcification. The Rotterdam Study (N=4,807, follow-up 10 years) found that the highest tertile of dietary K2 intake was associated with a 57% reduction in aortic calcification and a 52% reduction in all-cause mortality compared with the lowest tertile [9]. No equivalent signal was seen for K1.

This does not mean every person taking vitamin D3 must also take K2. People eating fermented foods, aged cheese, and organ meats typically have adequate K2 intake. Patients on warfarin must avoid K2 without hematology guidance, as even small amounts of menaquinone-7 can destabilize INR control.

A practical three-tier decision framework for calcium and vitamin D supplementation:

Tier 1 (No supplement needed): Serum 25-OH-D above 30 ng/mL, dietary calcium above 1 to 000 mg/day, no fracture risk factors, no malabsorption syndrome. Annual reassessment at preventive visit suffices.

Tier 2 (Targeted supplementation): Serum 25-OH-D between 20 and 30 ng/mL, or dietary calcium between 600 and 1 to 000 mg/day, or postmenopausal status without confirmed osteoporosis. Start 1,000 to 2 to 000 IU D3 daily and close the dietary calcium gap with food-first strategies before adding a low-dose supplement (500 mg or less elemental calcium per dose, calcium citrate preferred in adults over 60 or on proton pump inhibitors).

Tier 3 (Therapeutic supplementation with monitoring): Confirmed deficiency (25-OH-D below 20 ng/mL), osteoporosis or fragility fracture, glucocorticoid use exceeding 5 mg/day prednisone for three or more months, confirmed malabsorption. Loading doses of 50 to 000 IU vitamin D2 or D3 weekly for 8 to 12 weeks (prescription-grade) under physician supervision, then maintenance 1,500 to 2 to 000 IU daily. Recheck 25-OH-D at 3 months.

Are Bisphosphonates Safe Long Term?

Bisphosphonates are safe and effective for three to five years in most patients, and the fracture-reduction evidence at that interval is strong. The fracture risk picture becomes more complex beyond five years of continuous oral therapy.

Alendronate (Fosamax) and zoledronic acid (Reclast) remain the most studied agents. The FLEX trial followed women who had taken alendronate for five years and then either continued for five more years or switched to placebo [10]. Women who continued alendronate had lower rates of clinical vertebral fractures (2.4% vs. 5.3%) but no significant difference in non-vertebral or hip fractures compared to those who discontinued. The 2016 ASBMR task force concluded that a drug holiday after three to five years of oral bisphosphonate therapy is appropriate for patients whose hip T-score remains above -2.5 and who have not had a recent vertebral fracture [10].

Two rare but serious adverse effects require monitoring. Atypical femoral fractures occur in approximately 3.2 to 50 per 100,000 person-years of bisphosphonate exposure, with risk rising after five years of use [11]. Osteonecrosis of the jaw occurs primarily in oncology patients receiving high-dose intravenous bisphosphonates; the risk in osteoporosis patients on oral therapy is estimated at 1 in 10,000 to 1 in 100,000 [12]. Both risks remain low in absolute terms but justify periodic reassessment and dose holidays.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "For patients at moderate fracture risk, a drug holiday after 3 to 5 years of oral bisphosphonate therapy is reasonable, with reassessment of fracture risk every 2 to 3 years during the holiday" [13].

For high-risk patients (hip T-score below -2.5, prevalent vertebral fracture, or ongoing glucocorticoid therapy), continuous treatment or switching to an anabolic agent such as teriparatide (Forteo) or romosozumab (Evenity) should be considered rather than a drug holiday.

How to Stop Prolia Safely

Stopping denosumab (Prolia) without a transition plan is clinically dangerous. This is one of the most under-recognized safety issues in osteoporosis management.

Denosumab is a RANK ligand inhibitor administered as a 60 mg subcutaneous injection every six months. It suppresses osteoclast activity throughout the dosing interval but provides no residual skeletal effect once the drug clears. After the last injection, RANKL rebounds sharply, driving a rapid burst of bone resorption. A 2021 systematic review in the Journal of Bone and Mineral Research identified 24 case series and cohort studies documenting multiple spontaneous vertebral fractures occurring 7 to 18 months after denosumab discontinuation, often in patients who had no prior vertebral fractures [14].

The Endocrine Society's 2022 clinical practice guideline states: "We recommend transitioning to a bisphosphonate after denosumab discontinuation in patients who have received two or more doses, to prevent rebound bone loss and multiple vertebral fractures" [15].

The standard transition protocol:

1. Administer the final planned Prolia injection on schedule. Do not simply let the next injection lapse.
2. Begin oral alendronate 70 mg weekly or zoledronic acid 5 mg IV approximately six months after the last Prolia injection (timed to coincide with when Prolia's effect wanes).
3. Monitor bone turnover markers (serum CTX, P1NP) at 3 and 6 months post-transition to confirm suppression of rebound resorption.
4. Continue bisphosphonate for at least 12 months; some guidelines suggest two years for patients with pre-existing vertebral fractures.

Patients who cannot tolerate bisphosphonates may transition to raloxifene or hormone therapy, though evidence for these alternatives in preventing denosumab-discontinuation fractures is weaker.

DEXA T-Score vs. Z-Score: What Each Number Actually Means

The T-score and Z-score from a dual-energy X-ray absorptiometry (DEXA) scan answer different clinical questions. Confusing them leads to incorrect diagnoses.

The T-score compares a patient's bone mineral density to the mean peak bone density of a young adult reference population of the same sex. The World Health Organization defined the diagnostic thresholds in 1994 based on hip and spine measurements [16]:

• T-score at or above -1.0: normal bone density
• T-score between -1.0 and -2.5: osteopenia (low bone mass)
• T-score at or below -2.5: osteoporosis
• T-score at or below -2.5 with a fragility fracture: severe osteoporosis

The Z-score compares the patient's bone density to an age-, sex-, and ethnicity-matched reference population. A Z-score below -2.0 suggests bone density is lower than expected for the patient's age. This is the relevant number in younger patients (premenopausal women, men under 50, children), where low bone density may indicate a secondary cause such as hyperparathyroidism, celiac disease, anorexia nervosa, or glucocorticoid excess rather than age-related loss.

A 52-year-old postmenopausal woman might have a T-score of -2.7 (osteoporosis) and a Z-score of -0.5 (normal for her age group). That Z-score tells the clinician the bone loss is likely age- and estrogen-depletion-driven, not from a secondary pathology. A 38-year-old woman with a Z-score of -2.4 warrants a full secondary osteoporosis workup regardless of her T-score.

The Fracture Risk Assessment Tool (FRAX), developed by the WHO Collaborating Centre at Sheffield, integrates femoral neck T-score with clinical risk factors to estimate 10-year fracture probability. The NOGG (National Osteoporosis Guideline Group) and AACE both recommend FRAX-guided treatment thresholds rather than T-score alone [13]. A FRAX 10-year major osteoporotic fracture probability above 20%, or hip fracture probability above 3%, generally meets the threshold for pharmacologic treatment in the United States.

Do Weighted Vests Help Bone Density?

Weighted vests add measurable benefit when combined with resistance or impact training. Walking alone with a weighted vest probably does not produce clinically significant bone density gains in most populations, but the combination of a vest with progressive loading does.

Mechanical loading stimulates osteoblast activity through a process called mechanotransduction. Strain rates above approximately 1,500 microstrain are required to trigger new bone formation; ordinary walking generates 400 to 800 microstrain at the hip [17]. A weighted vest increases ground reaction forces and axial loading, raising strain closer to the osteogenic threshold.

The LIFTMOR-M trial (Watson et al., N=93 men with low-to-very-low bone mass) compared high-intensity resistance and impact training (HiRIT) to a machine-based low-intensity program over 8 months [18]. The HiRIT group, which used loaded barbells and jump landings rather than vests specifically, showed a 1.8% net gain in femoral neck BMD vs. a 1.3% loss in the control group (P<0.001). The spine showed a 2.9% net advantage for HiRIT.

The LIFTMOR trial in postmenopausal women with osteopenia or osteoporosis (Watson et al., 2018, N=101) found that 8 months of supervised HiRIT produced a 2.9% increase in lumbar spine BMD and a 0.3% increase in femoral neck BMD vs. a low-intensity control, with no serious adverse events [19].

Weighted vest walking specifically was examined in a 12-month RCT by Roghani et al. in older women: vests loaded to 4% to 6% of body weight during 45-minute walks three times per week produced modest but statistically significant gains in lumbar spine BMD (+1.2%) compared to unweighted walkers [20].

The practical minimum for a vest to be osteogenic is approximately 4% to 10% of body weight. Starting at the lower end and progressing over 4 to 8 weeks reduces injury risk. Patients with established vertebral fractures or severe osteoporosis (T-score below -3.0) should have exercise programming supervised by a physical therapist before adding weighted vests, as axial loading on a compromised spine carries fracture risk.

Optimizing Bone Health Across the Lifespan: What a Protocol Actually Looks Like

Bone density peaks between ages 25 and 35, declines slowly through middle age, and then accelerates in women during the first five to seven years after menopause, with losses of 1% to 3% per year at the spine during that window [21]. Building the largest possible peak bone mass before age 30, and then defending it afterward, are the two strategic objectives.

For adults under 50 with no risk factors, the protocol is dietary. Achieve 1 to 000 mg calcium per day from food, maintain serum 25-OH-D above 30 ng/mL (typically 1,000 to 2 to 000 IU D3 daily in northern latitudes from October through April), and perform at least 150 minutes per week of weight-bearing aerobic activity plus two sessions of resistance training per week per the 2018 Physical Activity Guidelines for Americans [22].

For postmenopausal women and men over 70, DEXA screening is appropriate. The National Osteoporosis Foundation recommends screening all women aged 65 and older and younger postmenopausal women with at least one major risk factor [23]. When pharmacologic therapy is indicated, bisphosphonates remain the first-line choice. Alendronate 70 mg once weekly reduces vertebral fracture risk by approximately 47% and hip fracture risk by 51% over 3 years compared to placebo in women with established osteoporosis, as shown in the FIT trial (N=2,027) [24].

For patients at high fracture risk (T-score below -2.5 with risk factors, or prior fragility fracture), anabolic therapy with teriparatide 20 mcg subcutaneous daily for up to 24 months or romosozumab 210 mg subcutaneous monthly for 12 months should be considered before cycling to an antiresorptive agent.

Hormone therapy warrants mention. Estrogen-based HRT prevents postmenopausal bone loss with well-documented efficacy; the WHI showed a 34% reduction in hip fracture risk at a mean follow-up of 5.2 years with conjugated equine estrogen plus medroxyprogesterone acetate [25]. For recently menopausal women under 60 who are candidates for HRT on other grounds (vasomotor symptoms, quality of life), bone protection is a legitimate additional benefit to weigh.